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Abstract: Following their initial discovery in the 1940s, polymyxin antibiotics fell into disfavor due
to their potential clinical toxicity, especially nephrotoxicity. However, the dry antibiotic development
pipeline, together with the rising global prevalence of infections caused by multidrug-resistant
(MDR) Gram-negative bacteria have both rejuvenated clinical interest in these polypeptide antibiotics.
Parallel to the revival of their use, investigations into the mechanisms of action and resistance to
polymyxins have intensified. With an initial known effect on biological membranes, research has
uncovered the detailed molecular and chemical interactions that polymyxins have with Gram-negative
outer membranes and lipopolysaccharide structure. In addition, genetic and epidemiological studies
have revealed the basis of resistance to these agents. Nowadays, resistance to polymyxins in
MDR Gram-negative pathogens is well elucidated, with chromosomal as well as plasmid-encoded,
transferrable pathways. The aims of the current review are to highlight the important chemical,
microbiological, and pharmacological properties of polymyxins, to discuss their mechanistic effects on
bacterial membranes, and to revise the current knowledge about Gram-negative acquired resistance
to these agents. Finally, recent research, directed towards new perspectives for improving these old
agents utilized in the 21st century, to combat drug-resistant pathogens, is summarized.
Keywords: polymyxins; colistin; outer membrane; lipopolysaccharide; mcr; antibiotic resistance;
Gram-negative pathogens

1. Introduction
The progressive global rise and dissemination of multidrug-resistant (MDR) bacteria represent
an enormous threat to humans today, and a main concern to public health and modern health care
systems [1]. Given their distinctive cellular features, Gram-negative bacteria are said to specifically
develop and acquire dynamic resistance patterns and cause significant morbidity and mortality
worldwide. Among these, carbapenem-resistant Enterobacteriaceae, MDR Pseudomonas aeruginosa,
and MDR Acinetobacter baumannii represent serious pressures to antimicrobial therapy, due to the
extremely limited efficacious treatment options [2]. Against such pathogens, polymyxins represent
one of the last-resort antibiotics that is still effective [3], among few others, including fosfomycin,
ceftazidime/avibactam and the recently approved meropenem–vaborbactam [4,5]. Polymyxins have
recently been invigorated as a class of bactericidal drugs that disrupt the outer cell membrane, and with
their revival, studies to understand their effects on bacterial cells were also actively restarted [6].
Nevertheless, the utility of polymyxins is currently facing a worldwide increasing resistance, particularly
due to the plasmid-encoded mobilized colistin resistance (mcr) gene present in pathogens such as
Escherichia coli and Klebsiella pneumoniae [7]. Polymyxins are definitely relevant in the context of biological
membranes study, since the Gram-negative outer membrane represents their first and foremost target.
In this paper, the main properties, mechanism of action, resistance pathways, and forthcoming clinical
and research directions for polymyxins are reviewed.
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Of all five polymyxins, only polymyxin B and colistin were put into clinical use in the 1950s,
as they were found to be the least nephrotoxic. Eventually, these antibiotics fell out of favor and their
systemic use waned due to their significant adverse effects, especially their potential for nephrotoxicity
and neurotoxicity [12,13]. Early medicinal chemistry efforts with polymyxins in the 1970s aimed
at modifying their structures to improve their safety. However, the majority of these trials were
limited to modifications to the peripheries of the polymyxin structure, namely the acylation/alkylation
of the side-chain amino groups of the Dab residue, or the substitution of the N-terminal fatty acyl
chain [8]. At that time, the lack of robust synthetic platforms that allow the total synthesis of polymyxin
lipopeptides, as well as the limited understanding of polymyxin pharmacology, were a barrier to
obtain more tolerable and effective compounds [13], and their clinical use dramatically declined [14].
This was concurrent with the emergence of less-toxic aminoglycosides and other antipseudomonal
agents [15]. Nevertheless, interest in polymyxin B and colistin has risen substantially in the last two
decades, with the emergence of MDR Gram-negative organisms nonresponsive to other clinically
available antibiotics [16,17]. In this review, and unless otherwise indicated, the term polymyxins shall
be used to refer to the two clinically useful compounds, polymyxin B and colistin.
3. Clinically Useful Polymyxins and Their Principle Properties
Despite minor differences, polymyxin B and colistin have comparable chemical structures,
mechanisms of action, and spectra of activity. However, they have different pharmacokinetics
and pharmacodynamics. The sections below address the essential properties of the two clinically
useful compounds.
3.1. Chemical Properties and Structure–Activity Relationships
Colistin and polymyxin B differ by a single amino acid at position 6 in the peptide ring, as shown
in Figure 1, with a D-phenylalanine in polymyxin B and a D-leucine in colistin [18]. Both drugs are
highly basic due to five free amino groups [19]. Polymyxin B is primarily composed of a mixture of two
polypeptides, polymyxin B1 and polymyxin B2; colistin is primarily composed of a mixture of colistin
A (also known as polymyxin E1) and colistin B (also known as polymyxin E2). The difference between
these four compounds is the fatty acid substitution of the lipopeptide structure, where it consists of
6-methyloctanoic acid in polymyxins B1 and E1, and of 6-methylheptanoic acid in polymyxins B2
and E2 (Figure 1) [20].
Although the mechanistic action of polymyxin B and colistin shall be deliberated exquisitely
later in this review, it is important to mention, in context of their structure, that their chemistry
is critical to their antibacterial activity [18]. The primary amines of the Dab residues are ionized
at physiological pH, allowing the polymyxin molecules to carry a net polycationic charge, a vital
characteristic for their interaction with negatively charged phosphate groups of the lipid A of bacterial
lipopolysaccharide (LPS). In addition, polymyxins possess hydrophobic domains, namely the fatty acyl
side chain, and these are able to interact with corresponding LPS structures [21]. Therefore, as a result
of such assembly of hydrophilic and lipophilic entities, polymyxins are amphipathic and capable of
both ionic and hydrophobic molecular interactions at the bacterial outer membrane level, contributing
to their mechanism of action [13]. Studies from models using monolayers of LPS of Gram-negative
bacteria indicate that chemical cationic amphipathicity determines polymyxin activity [22].
A deep understanding of the structure–activity relationships of polymyxins has been established,
including the capacity of their three-dimensional structure to interact with bacterial membranes [23].
Polymyxins initially act by binding to lipid A of LPS, whose anionic nature facilitates the electrostatic
interaction with the cationic polymyxins. This primary interaction leads to the disruption of bacterial
outer membrane and the hydrophobic insertion of the fatty acyl chain of polymyxin into lipid A.
Subsequently, cytoplasmic membrane disruption and the potential additional intracellular interactions
lead to cell death [24]. Important contributions were made by the N-terminal fatty acyl chain
of polymyxins to binding with LPS and consequent antibacterial activity. A comparison across
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different N-terminal fatty acyl chains documented that antimicrobial activity correlated with the length
and bulkiness of the N-terminal fatty acid, where seven to nine carbon atoms are optimal for binding
affinity [13].
Another important structural feature of the polymyxins, vital for their activity, is the presence
of multiple positively charged Dab side chains, which interact with the phosphate groups on lipid
A [8]. The key features of the Dab residues that are important for LPS binding affinity include the
cationic character, the two methylene groups of the Dab side chain, and the characteristic order of
the Dab residues within the primary polymyxin sequence that confers the proper spatial distribution
of the positive charges for electrostatic interactions with the phosphates of lipid A. Overall, the Dab
residues, particularly those lying within the cyclic heptapeptide, are indispensable for antimicrobial
activity [13,25]. Furthermore, polymyxins contain D-phenylalanine and L-leucine at the amino acid
positions 6 and 7, respectively, in the fatty acid chain of polymyxin B, and D-leucine and L-leucine at
positions 6 and 7, respectively, in colistin, within the heptapeptide ring. These amino acids ensure a
hydrophobic motif believed to insert into the bacterial outer membrane and stabilize LPS complexation,
via hydrophobic interactions with the fatty acyl chains of lipid A [26]. Finally, the particular combination
of topographic chemical features and the special configuration of the polymyxin ring structure appears
ideal for efficient binding to LPS and the subsequent membrane permeabilizing effect. Previous
attempts to produce an extended ring structure, generated by the insertion of additional Dab residues,
yielded resultant compounds that were significantly less active than polymyxins [27].
3.2. Spectrum of Antibacterial Activity
Polymyxins demonstrate important activity against Gram-negative aerobic pathogens, including
most members of the Enterobacteriaceae family, E. coli, Enterobacter spp., Klebsiella spp., Citrobacter
spp., Salmonella spp., and Shigella spp [12]. Additionally, they are effective against non-fermentative
Gram-negative common pathogens, including A. baumannii and P. aeruginosa. The breakpoints of
sensitivity for Enterobacteriaceae, Pseudomonas, and Acinetobacter according to the 2020 internationally
adopted guidelines are shown in Table 1 [28,29]. These breakpoints correspond to the minimum
inhibitory concentration (MIC) used to categorize strains as sensitive, resistant, or intermediate in
their response to polymyxins. In vitro susceptibility was reported for Stenotrophomonas maltophilia [30].
Notable exceptions of Gram-negative bacteria that are naturally resistant to polymyxins comprise
Pseudomonas mallei, Morganella morganii, Vibrio cholerae, Serratia marcescens, Proteus spp., Providencia
spp., Burkholderia cepacia, Chromobacterium spp., Edwardsiella spp., Brucella, Legionella, and Campylobacter.
Polymyxins are not active against Gram-negative cocci (such as Neisseria spp.), nor against Gram-positive
and anaerobic bacteria, parasites or fungi [31].
Table 1. Minimum inhibitory concentration (MIC) breakpoints of colistin sensitivity according to the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) and of colistin/polymyxin B
sensitivity according to Clinical Laboratory and Standards Institute (CLSI).
EUCAST Breakpoints (mg/L)

Enterobacteriaceae
Pseudomonas
Acinetobacter

CLSI Breakpoints

S≤

R>

I≤

R≥

2
2
2

2
2
2

2
2
2

4
4
4

S = sensitive; R = resistant; I = Intermediate.

Modifications in lipid A of LPS are associated with the innate resistance seen in bacteria intrinsically
resistant to polymyxins [32]. For example, in Proteus mirabilis, the expression of a seven-gene
operon, called the pmrHFIJKLM homologue, is involved in LPS modification, leading to polymyxin
resistance [33]. In Brucella melitensis, lowering the phosphoethanolamine (pEtN) content of the cell
envelope, using the enzyme BveA, a type of phospholipase, increases B. melitensis resistance to
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polymyxin B [34]. Conversely, in Campylobacter jejuni, modifying lipid A by the addition of pEtN, using
the catalytic action of the enzyme pEtN transferase, promotes polymyxin resistance [35]. Nevertheless,
recent research on the in vitro activity of colistin against C. jejuni and Campylobacter coli, obtained from
fecal material of patients with severe diarrhea, have shown low inhibitory values [36]. The question
whether colistin may represent an alternative to fluoroquinolones and tetracyclines for the treatment
of severe diarrhea produced by these species warrants additional investigation.
3.3. Administration and Clinical Uses
Polymyxin B and colistin harbor different modes of administration to maintain activity [37].
Polymyxin B is administered as the active antibacterial compound, polymyxin B sulfate, which is given
intravenously. Polymyxin B is not absorbed from the gastrointestinal tract. Topical, nonabsorbable
oral, and ophthalmic formulations are available. Additional routes of administration include inhaled
and intrathecal administration [38].
In contrast, colistin is administered parenterally as a prodrug, colistin methanesulfonate, also
named colistimethate sodium (CMS), which is considered less toxic than the parent drug, colistin
sulfate, upon parenteral administration [39]. CMS itself lacks intrinsic antibacterial activity; it should be
converted in vivo into colistin after its administration [18,40]. In chemical synthesis, CMS is produced
via an interaction of colistin with formaldehyde and sodium bisulfite, leading to a sulfomethyl
group being added to the primary amines of colistin [41]. As such, colistin and CMS also differ in
administration: Colistin is primarily used topically, whereas CMS is used parenterally, and both may
be given by inhalation [42].
3.3.1. Systemic Use
Due to their poor oral absorption, orally administered polymyxins are only used for digestive tract
disinfection. Moreover, polymyxins do not efficiently diffuse into tissues, neither do they penetrate the
cerebrospinal fluid, nor the pleural and peritoneal cavities [43]. Nevertheless, polymyxins are used
systemically by intravenous administration for serious infections due to pathogens resistant to other
effective therapies. They are indicated for the treatment of diverse infections, including pneumonia,
bacteremia, urinary tract infections, bone and joint infections, burn infections, endocarditis, cellulitis,
cystic fibrosis, gynecologic infections, meningitis, and ventriculitis [44]. Whether polymyxin B or
colistin are preferable for systemic administration is debatable. Some trials suggest that polymyxin
B achieves adequate drug levels more rapidly and reliably than colistin, the latter being a prodrug.
An exception may be infections of the urinary tract, where colistin appears to be more effective
and reaches high urinary levels, probably due to the extrarenal clearance of polymyxin B, keeping
its urinary concentrations low [18,45]. Inhaled forms of both polymyxin B and colistin are available,
and are given via a nebulizer to reach the lungs for the management of chronic pneumonia caused by P.
aeruginosa in cystic fibrosis patients. However, because polymyxin B is more likely to cause airway
obstruction, colistin is generally preferred for this indication [46]. The intrathecal and intraventricular
administration of either polymyxin B or colistin is useful for central nervous system infections due to
MDR Gram-negative bacteria, as an adjunct to systemic antibiotic therapy. As for the inhaled route,
clinical experience, safety, and efficacy appear to be higher for intrathecal and intraventricular colistin,
while experience with polymyxin B via these routes is limited [47].
3.3.2. Topical Use
Polymyxin B sulfate is available for ophthalmic, otic, and topical use in combination with a
variety of other compounds, while colistin is available as otic drops [48]. Polymyxin B is used with
bacitracin as an opthalmic ointment, while it is available with neomycin as a urinary bladder irrigant for
short-term use (up to 10 days) in abacteriuric patients to help prevent bacteriuria and Gram-negative
rod septicemia associated with the use of indwelling catheters. It is also available with both bacitracin
and neomycin as a topical antibiotic [49]. Infections of the skin, mucous membranes, eye, and ear due
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to sensitive microorganisms respond to the local application of polymyxin B in solution or ointment
form. External otitis, frequently due to Pseudomonas, may also be cured by the topical use of the drug.
P. aeruginosa is a common cause of infection of corneal ulcers; the local application or subconjunctival
injection of polymyxin B is often curative [50].
3.4. Pharmacokinetics
Polymyxin B is administered directly in its active antibacterial form, and is subject to very extensive
renal tubular reabsorption and thus primarily undergoes nonrenal clearance. Pharmacokinetic data on
polymyxin B are limited. Over 95% of polymyxin B is cleared independently of the kidneys. Little is
known about its extravascular distribution or penetration into other tissues, but it is thought to be
similar to that of colistin, with generally poor penetration into the lungs, pleura, bones, and central
nervous system [38].
Unlike polymyxin B, and following parenteral administration, about 20–25% of the dose of CMS
prodrug is hydrolyzed in vivo into an active colistin entity, while a large proportion of the prodrug
is eliminated mainly through the kidneys by glomerular filtration and tubular secretion [51]. CMS
(but not colistin) is cleared renally; thus, the modification of the dose is generally required in patients
with impaired renal function. Therefore, colistin concentrations resulting from the original CMS
administration are low. In contrast to CMS, colistin is eliminated predominantly by nonrenal pathways
because of its extensive renal tubular reabsorption. Although colistin is poorly excreted in urine,
the urinary concentration of colistin may be relatively high after the administration of CMS, since the
conversion of most colistin recovered in the urine is from the post-excretion hydrolysis of CMS into
colistin within the urinary tract [12]. Colistin is tightly bound to membrane lipids of the cells in many
body tissues, including the liver, lung, kidney, brain, heart, and muscles. The half life of colistin
following IV administration is about 2–3 hours in subjects with normal renal function, and it is about
50% protein bound [37].
3.5. Toxicity
Perhaps the most common and clinically significant adverse effect of intravenous polymyxins is
nephrotoxicity, which has an incidence of 50–60% in patients receiving polymyxin B or colistin [52],
with expert opinion suggesting that the relative risk of nephrotoxicity is not significantly different among
the two compounds [53]. Polymyxins have correlations with hematuria, proteinuria, oliguria, and acute
kidney injury. Therefore, renal function should be monitored closely during administration, and the
concurrent use of other nephrotoxic drugs should be avoided whenever possible [54]. The plasma
concentrations of polymyxins associated with the increased risk of acute renal failure intersect with
those required for antibacterial effect, rendering these drugs of narrow therapeutic index, a quantitative
measurement of the relative safety of a drug that compares the amount that causes the therapeutic effect
to the amount that causes toxicity [55]. The requirement for the conversion and recycling of polymyxins
in the kidneys, as described above, makes the proximal tubular cells of the kidney the major location
where polymyxins accumulate, while their concentrations are much lower in the liver, heart, lungs,
spleen, and muscles [56]. Cell line investigations and in vivo preclinical models studying polymyxins
toxicity on renal tubular cells suggest several cellular mechanisms. These include oxidative stress,
apoptosis, cell cycle arrest, and autophagy [57]. The nephrotoxic potential of polymyxins is associated
with their chemical structure. Attempts for the complete removal of the N-terminal fatty acyl group,
considered a nephrotoxicity “hot-spot”, or to decrease its hydrophobicity, thereby reducing its uptake
by renal tubular cells, produced derivatives with reduced nephrotoxicity. However, this occurred at
the expense of significantly reduced antibacterial activity compared with polymyxin B and colistin [8].
Added to nephrotoxicity, hypersensitivity reactions, manifested as rash, pruritus, urticaria,
and fever have been reported with the systemic use of polymyxins, [54], as well as neurotoxicity, seen in
about 7% of patients. The latter is clinically characterized by symptoms of dizziness, visual disturbance,
ataxia, vertigo, confusion, hallucinations, seizures, and facial and peripheral paresthesias. The use of
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other neurotoxic drugs concomitantly should be avoided [58]. It is believed that such manifestations
result from the injury and death of neuronal cells, largely caused by reactive oxygen-induced oxidative
stress and mitochondrial dysfunction, followed by apoptosis and autophagy [59,60]. Experimental
trials for the scavenging of reactive species and halting apoptosis in cell lines using certain agents
claimed to be neuroprotective, such as minocycline and rapamycin, are underway [59,61,62]. Finally,
apart from the above adverse effects and in some reports, skin hyperpigmentation was documented
with intravenous polymyxin B, and was associated with melanocyte activation and inflammatory
process in the skin [63,64].
4. Mechanism of Action of Polymyxins and Proposed Interactions with Bacterial Membranes
and Other Cellular Structures
4.1. Overview
The study of mechanistic pathways used by polymyxins to kill Gram-negative bacteria has
been the subject of extensive research. The expanding interest in the use of these antibiotics with
a focus on their mechanism of antibacterial activity, and the subsequently emerging resistance in
Gram-negative bacteria, has been nicely described in previous reviews [12,65]. Even though the details
of the antibacterial activity of these compounds are yet to be thoroughly understood, their initial
interaction with bacterial membranes is indispensable [21]. In this context, polymyxins, basic peptides
with a molecular weight of about 1000 Da, act as surface-active amphipathic agents or cationic
detergents. They interact strongly with phospholipids and disrupt the structure of cell membranes.
Specifically, polymyxins bind to LPS and phospholipids in the outer cell membrane of Gram-negative
bacteria. They competitively displace divalent cations from the phosphate groups of membrane lipids,
which leads to the destabilization of the outer cell membrane, the leakage of intracellular contents,
and bacterial cell death [66].
To properly comprehend the mechanism of action of polymyxins, an understanding of the outer
membrane structure in Gram-negative bacteria is imperative. This membrane surrounds a thin
peptidoglycan layer, and comprises an exclusive architecture, not found in Gram-positive bacteria [67].
Its structure allows it to be a potent selective permeability barrier against harmful molecules, such as
detergents antibiotics [68]. The outer membrane organization and the binding of polymyxins are
shown in Figure 2.
The chemical composition of the outer membrane is heterogeneous, with phospholipids,
LPS, outer membrane proteins, and lipoproteins [69]. Such a blend of chemical components is
arranged asymmetrically, where a bilayer of phospholipids, similar to other biological membranes,
exists in the inner leaflet, and LPS in the outer leaflet, with anchored lipoproteins and outer
membrane proteins [70]. Phospholipids of the outer membrane include different molecules,
such as phophatidylethanolamine, phosphatidylglycerol, and cardiolipin [70]. Regarding the
outer membrane anchored lipoproteins, these play a key role in the linkage between the outer
membrane and peptidoglycan, peptidoglycan biosynthesis, flagellar assembly, and protein secretion
and polysaccharide secretion [68,71]. Outer membrane proteins act as porins, specific and non-specific
channels that regulate the transport of hydrophilic molecules across the outer membrane [72]. On the
other hand, the LPS is a complex, glucosamine-based glycolipid unique to Gram-negative bacteria. It is
composed of lipid A, core oligosaccharide, and O-antigen polysaccharide chains, and plays a critical
role in the barrier function of the outer membrane [73]. Lipid A (endotoxin) is a powerful stimulator of
human immune response, and is released upon bacterial death, resulting in the secretion of a number
of proinflammatory cytokines from monocytes and macrophages, with the resulting possibility of
Gram-negative sepsis [74,75]. The chemical structure of lipid A consists of D-glucosamine disaccharide
that is phosphorylated at the 10 - and 40 positions, with fatty acid esters attached to both carbohydrates.
The fatty acyl chain length may vary between bacterial species, but is typically conserved within a
given species. The lipid A chains are tightly packed together within the outer membrane through
van der Waals forces, while divalent calcium and magnesium cations associated with lipid A act to
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polymyxins bind to LPS and phospholipids in the outer cell membrane of Gram-negative bacteria.
lies on the outer membrane at the side of the phospholipid bilayer. Meanwhile, a non-repeating
They competitively displace divalent cations from the phosphate groups of membrane lipids, which
core oligosaccharide and a distal polysaccharide (also known as O-antigen or somatic-antigen) line
leads to the destabilization of the outer cell membrane, the leakage of intracellular contents, and
the external portion of LPS, which extends to outside of the cell. Oligosaccharides are involved in
bacterial cell death [66].
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hydrophilic molecules. The outer membrane lipoproteins float among other components, giving
such as detergents antibiotics [68]. The outer membrane organization and the binding of polymyxins
the outer membrane an overall sophisticated composition, that is efficient to protect against toxic
are shown in Figure 2.
substances and stressful environmental conditions [78].
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4.2. Insights into Models of Polymyxins’ Mechanism of Action
In fact, the exact mode of action of polymyxins lingers to be argumentative. Despite an overall
assumption for the membrane as the primary drug target for polymyxins, there is evidence for
alternative or complementary pathways, and literature has described several models.
In one model based on outer membrane damage, consensus opinion focuses on a number of
steps: (1) the initial uptake of polymyxin into the bacterial outer membrane is “self-promoted” [21].
In this process, polymyxins, with cationic affinity to LPS at least three-fold higher than that of the
native divalent cations, calcium and magnesium, competitively displace these ions and, being bulky,
disrupt the normal barrier property of the outer membrane. The affected outer membrane is thought
to develop temporary “cracks”, that permit the passage of various molecules, among which is the
uptake of the polymyxin itself [79]. (2) Following this uptake, an electrostatic interaction occurs
between the Dab residue of the positively charged polymyxin on one side, and the phosphate groups
of the negatively charged lipid A, making lipid A the principle polymyxin-binding target in the outer
membrane of Gram-negative bacteria [13]. (3) Divalent calcium and magnesium cations are displaced
from the negatively charged phosphate groups of membrane lipids [12], and this displacement allows
the hydrophobic fatty acyl tail of the polymyxin molecule to be inserted into the outer membrane [79].
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(4) Such insertion weakens the packing of adjacent lipid A fatty acyl chains, causing outer membrane
expansion [13]. (5) Eventually, such expansion facilitates the formation of destabilized areas through
which polymyxin crosses the outer membrane. Finally, polymyxins will destroy the physical integrity
of the phospholipid bilayer of the cytoplasmic (inner) membrane, and intracellular contents begin to
leak out, resulting in cell death [3,26].
Apart from such steps, and in other models, polymyxin is thought to mediate the fusion of
the inner leaflets of the outer membrane and the outer leaflet of the inner membrane surrounding
the periplasmic space [80]. Such action is believed to induce phospholipid exchange, between the
leaflets of the inner and outer membranes, triggering a loss of specificity of phospholipid composition.
This can potentially cause an osmotic imbalance that culminates in cell death [22]. Such a pathway,
in which polymyxins bind to both anionic phospholipid vesicles, namely, inner phospholipid leaflets
of outer membrane and inner membrane, promote phospholipid exchange between vesicles, is called
the vesicle–vesicle contact pathway. The mechanism for the intermembrane transfer of phospholipids
could be responsible for the intracellular trafficking and sorting of phospholipids; it could be a necessary
step for polymyxin antibiotic action [81]. Moreover, hydrophobic interactions are assumed to occur
between the N-terminal fatty acyl tail of the polymyxin molecule and the fatty acyl chains of lipid A [82].
The result of a dynamic simulation study on a laboratory strain of E. coli predicted that polymyxin B1 is
likely to interact with both the inner and outer membranes via distinct mechanisms. While polymyxin
B1 molecules aggregate in the LPS region of the outer membrane with restricted insertion within the
lipid A tails, they readily insert into the inner membrane core. The concomitant increased hydration
may be responsible for bilayer destabilization and antimicrobial function [83].
A third model of polymyxins’ activity involves free radical-induced death. In bacterial cells,
the activity of redox enzymes extracts the electrons from molecular oxygen, continuously forming
intracellular superoxide, hydroxyl radical, and hydrogen peroxide. These species adversely affect the
activities of enzymes and the integrity of DNA, lipids, and proteins, thereby compelling organisms
to protect themselves with a response involving repair systems and enzymes. However, elevated
levels of oxidants will eventually poison bacteria [84]. Superoxide levels are postulated to rise when
polymyxin molecules enter across the Gram-negative cell wall; superoxide will be enzymatically
converted to hydrogen peroxide by cellular superoxide dismutases. Then, hydrogen peroxide will
oxidize ferrous iron to ferric iron, forming a hydroxyl free radical. When the concentration of the latter
reaches significant levels, it will stimulate oxidative damage of biological molecules with deleterious
effects on the cell, which are independent of polymyxin binding to its specific target in the outer
membrane [85]. Therefore, it is suggested that some antibiotics, including polymyxin B and colistin,
but also others like kanamycin, kill bacteria through oxidative stress and reactive oxygen species
(ROS) generation [3]. The applicability of such a mechanism to polymyxin has been investigated in
several studies. For instance, sublethal concentrations of polymyxin B induced an oxidative burst
and high endogenous ROS production in P. aeruginosa [86]. Moreover, a hydroxyl radical scavenging
compound, thiourea, was assessed regarding its ability to prevent the polymyxin-induced killing of
A. baumannii. A striking decrease in the ability of both polymyxin B and colistin to kill A. baumannii was
noticeable in the presence of thiourea, which acted as a “rescue” compound [87]. In 2015, Dong et al.
showed that polymyxin stimulates the generation of ROS, but cell killing could occur by nonoxidative
mechanism, typically envelope disruption. Furthermore, polymyxin stimulates the expression of a
gene called soxS (for superoxide response) in E. coli, whose expression may be a strategy to prepare
for the potentially lethal interactions with diffusible toxic molecules, including polymyxin. The gene
soxS encodes a transcriptional activator of genes that respond to reactive oxidative (redox) stress,
such as sodA (Mn-containing superoxide dismutase), fpr (NADPH:ferredoxin oxidoreductase), and ydbK
(a putative Fe-S-containing reductase) [88]. Interestingly, in 2017, it was shown that colistin induced
ROS accumulation and oxidative stress-induced damage in P. polymyxa, the producer of colistin.
This highlighted an unfamiliar activity of colistin against Gram-positive bacteria [89]. Moreover,
the membrane damage and extensive cell surface alteration in Gram-positive bacteria was revealed
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by detecting the leakage of intracellular molecules, shedding light on a not yet described bactericidal
mechanism of polymyxin E against Gram-positive bacteria [90].
Additional systems of polymyxin activity have been proposed. By binding to the LPS molecule
released upon the cell lysis of Gram-negative pathogens, polymyxins cause the neutralization of
the endotoxin, corresponding to lipid A of LPS, diminishing its pathophysiologic effects in the
circulation [12]. Moreover, Deris et al. showed that polymyxins inhibited key respiratory enzymes,
such as type II NADH-quinone oxidoreductases, which exist in the bacterial inner membrane of three
Gram-negative species: E. coli, K. pneumoniae and A. baumannii, suggesting this pathway as a secondary
polymyxin mode of action [91]. A recent study showed the enhancement of NADH metabolism and the
resulting generation of oxidative damages in Gram-positive cells of Bacillus subtilis and P. polymyxa,
giving insights into a yet unrevealed action of polymyxin in Gram-positive cells [92]. Additionally,
a significant decrease in dividing cells was observed when P. aeruginosa were treated with colistin,
although without significant killing [93]. In this report, an increase in cellular rigidity was noticeable,
speculating that the binding of colistin to the outer membrane may stiffen the bacterial cell wall,
altering its nanomechanical properties and morphology, and perturbing normal cell division. McCoy
and colleagues [94] showed that polymyxins can bind to the 16S (prokaryotic) and 18S (eukaryotic)
A-site RNA constructs of ribosomes, where they interfere with eukaryotic translation in vitro, but not
with bacterial translation. Therefore, a possible mechanism for polymyxins by interference with
bacterial ribosomes was investigated, but appears unlikely. Recently, and using a metabolomic
approach, elevated glucose levels, and various glyoxylate and glycerolipid metabolic intermediates,
were observed in Mycobacterium tuberculosis cultured in the presence of colistin. The increase in
fatty acid synthesis and cell wall repair postulated that colistin acts by disrupting the cell wall in
M. tuberculosis, in a manner similar to other bacteria [95]. In Mycobacterium smegmatis, polymyxin B
inhibited the activity of the alternative NADH dehydrogenase and the malate: quinone oxidoreductase,
which are both respiratory enzymes [96]. The last two models perhaps justify interest in the applicability
of polymyxin as a potentiator of anti-mycobacterial drugs [97].
Overall, despite the traditional record of polymyxins as affecting bacterial membranes leading to
lysis and death, there is substantial work investigating secondary mechanisms. Polymyxins shuffle
phospholipids, mediate hydroxyl radical death pathways, counterbalance endotoxins, and affect normal
cell reproduction and respiration. It is hoped that a deeper understanding of the mechanisms of action
of these compounds will offer better insights into their pharmacological potential and clinical utility.
5. Bacterial Resistance to Polymyxins and Changes in Membranes
The use of polymyxins, among the few remaining valid options for the therapy of infections
caused by MDR Enterobacteriaceae, P. aeruginosa and A. baumannii, has prompted the emergence of
resistance to this antibiotic class, creating a major public health concern [98]. Bacterial resistance to
polymyxins may be chromosomal and associated with the modification of LPS, or may be encoded
on transposable genetic elements, namely mcr genes [43]. A representation of the current knowledge
regarding bacterial resistance to polymyxins is discussed below.
5.1. Chromosomal Resistance
Similar to bacterial species that are naturally resistant to polymyxins (described above), the change
in the LPS total charge is responsible for developing polymyxin resistance [12]. Chromosomal mutations
that lead to the addition of cationic groups to lipid A weaken the binding of polymyxins to their
main target [23]. Although the exact chromosomal mechanism for lipid A modification appears to
be species-specific, regulatory genes or operons such as PmrAB and PhoPQ trigger the chromosomal
mechanism and are shared by many species [99,100]. The role of these regulatory systems is to permit
bacterial cells to react to environmental changes by modifying their gene expression. When these
regulatory systems interact with one another, they even have more profound effects on polymyxin
resistance [101]. The net effect of the activity of these systems is the addition of cationic groups,

Membranes 2020, 10, 181

11 of 30

4-amino-4-deoxy-L-arabinose (L-Ara4N) and pEtN, to LPS, mediating the acquired resistance to
colistin [12]. Below is a panel of operons involved in this process:
1.

2.

3.

The PhoPQ two-component system and its regulatory gene mgrB. This system codes for two
proteins, the regulator protein PhoP and the protein kinase PhoQ. While the kinase senses a
specific environmental stimulus, the corresponding response regulator mediates the cellular
response, mostly through the differential expression of target genes. In the presence of certain
environmental stimuli, this system allows the expression of virulence factors, enzymes that
modify the LPS to allow resistance to cationic antimicrobial peptides, or enzymes that decrease
stress due to acidic pH. The PhoPQ two-component system promotes bacterial survival in low
magnesium concentration or in acidic pH or in the presence of cationic antimicrobial peptides.
PhoQ is a protein with tyrosine kinase activity that activates PhoP through phosphorylation [102].
Active PhoP drives the transcription of the pmrHFIJKLM operon, involved in the chemical
modification of LPS via the addition of L-Ara4N to the LPS. Moreover, PhoP can also activate
the pmrA gene, triggering the expression of PmrA protein, causing the addition of pEtN to the
LPS [103]. The regulation of the PhoPQ system occurs through the gene mgrB, which acts as a
negative regulator. Upon the activation of PhoP, the mgrB gene is upregulated. The translated
mgrB protein in turn represses the PhoQ gene. The inactivation of the mgrB gene leads to the
overexpression of the phoPQ operon, thus causing pmrHFIJKLM operon activation, leading to the
production of L-Ara4N responsible for the acquisition of polymyxin resistance. Studies show
that substitutions, insertions, or deletions in the mgrB gene mediate polymyxin resistance [12].
For example, in KPC-producing K. pneumoniae, the transcriptional upregulation of the PhoQ gene
was observed in the strains with mgrB alterations, mediating colistin resistance [104]. Although
mgrB mutations or inactivation were suggested as major mechanisms for colistin resistance in
K. pneumoniae [105–107], Borsa et al. reported an overexpression of PhoQ and phoP genes in K.
pneumoniae with wild-type mgrB gene, suggesting that other genetic regulations of the PhoPQ
system may exist [108]. A very recent report from Korea described the mgrB alteration mediating
colistin resistance in E. coli isolated from livestock [109]. It is noteworthy that the mutation of
genes other than mgrB may contribute to enhancing PhoPQ system activity, such as ColR/ColS
and CprR/CprS regulatory systems in P. aeroginosa [110], and cprR/cprS in C. jejuni [99].
The PmrAB two-component system. Similar to the PhoPQ system, the PmrAB system is a typical
two-component system, so it encodes both PmrA and PmrB. PmrB is a protein with tyrosine kinase
activity, that activates the transcriptional regulator PmrA by phosphorylation. Environmental
stimuli, such as macrophage phagosomes, ferric iron, aluminum ion, and low pH, activate
PmrB. PmrA in turn activates the transcription of the pmrCAB operon and the pmrHFIJKLM
operon, that are involved in LPS modification by the addition of pEtN and L-Ara4N [111].
Mutations causing constitutive activation in the pmrA and pmrB genes have been described as
being responsible for acquired colistin resistance [99]. Reports of such alterations are availble for
E. coli [112], Enterobacter cloacae [113], P. aeruginosa [114], and A. baumannii [115,116].
The lpxA, lpxC and lpxD genes. This unique set of genes exists in A. baumannii, which can
become highly resistant to polymyxins via spontaneous mutations in these lipid A biosynthesis
genes. If the biosynthetic lipidA genes, lpxA, lpxC, or lpxD, become inactive, LPS is not formed,
and interaction with polymyxins is lost [116]. In its attempt to adapt to the antibiotic pressure
induced by polymyxins, A. baumannii, through the inactivation of the aforementioned genes, loses
LPS, a major virulence factor and structural component. Such adaptation results in a dramatic
decrease in the fitness and virulence and major changes in the physiology, thus providing insights
into the low prevalence of polymyxin-resistant A. baumannii isolates with LPS loss in the clinical
setting [117].

In addition to the cationic modifications of lipid A, some studies indicated the prevalence of
other changes, such as outer membrane remodelling events, which may contribute to resistance.

Membranes 2020, 10, 181

12 of 30

The comparative profiling of the outer membrane proteome of a laboratory strain of extremely
colistin-resistant K. pneumoniae revealed that outer membrane proteins from bacterial stress response,
glutamine degradation, aspartate, pyruvate, and asparagine metabolic pathways were over-represented,
compared to sensitive strains [118]. In clinical strains of K. pneumoniae and Enterobacter asburiae,
matrix-assisted laser desorption ionization time of flight/mass spectrometry (MALDI-TOF/MS)
investigation done by a Hungarian research group identified the differences between outer membrane
proteins among colistin-susceptible and -resistant counterparts. While the colistin-susceptible
K. pneumoniae had 16 kDa proteins belonging to the LysM domain/BON superfamily, as well as
DNA starvation proteins, the colistin-resistant strains had OmpX and OmpW. Furthermore, OmpC
and OmpW were detected in the colistin-susceptible E. asburiae, whereas OmpA and OmpX were
identified in the colistin-resistant counterpart. This demonstrated that the altered Gram-negative
cell wall may contribute to acquired colistin resistance in Enterobacteriaceae [119]. Another study
investigated the influence of lipid A acylation pattern on the crucial interaction between the LPS of a
clinical K. pneumoniae isolate and polymyxins. The underacylation of lipid A resulted in increased
polymyxin susceptibility, with the hexa-acylated lipid A showing better interaction with polymyxins
than the penta-acylated lipid A, perhaps unraveling a novel appreciation of the mechanisms of
polymyxin activity and resistance [120].
5.2. Plasmid-Mediated Resistance
Until 2015, the identified mechanisms of polymyxin resistance were attributed to chromosomal
mutations, and not to horizontal gene transfer. However, it was found that polymyxin resistance could
also be dependent on plasmid-mediated and therefore the transferable genes, of the mobilized colistin
resistance (mcr)-type [121]. Such mobile resistance is ultimately rendering the “last resort” polymyxin
antibiotics therapeutically unusable, and is disseminating over wide geographic locations, as well as
among animals, water, food chain and the environment [122].
The first mcr gene, mcr-1, was identified in the E. coli of animal, human, and environmental
origin recovered in China in 2015, during the routine surveillance of antimicrobial resistance in E. coli
from food animals [123]. Being carried on a conjugative plasmid, mcr-1 exhibited an easily driven
dissemination into various bacteria from animals and humans. In light of a such transferability of
polymyxin resistance by mcr-1, it was not surprising that it rapidly swept across nearly the entire globe
in less than a year since its first discovery [124]. Eventually, different variants up to mcr-9 were identified
in various Gram-negative bacteria [43], and were reported beyond China in all continents [12]. In 2020,
a novel mcr gene, mcr-10, was identified on a plasmid of an Enterobacter roggenkampii clinical strain [125].
A summarized description of the known mcr genes to date is shown in Table 2. The mcr-1 gene is
responsible for polymyxin resistance through encoding a pEtN transferase. This enzyme, similar to
chromosomal resistance pathways, especially those associated with two-component systems, mediates
the addition of pEtN to lipid A, making this compound highly cationic [126]. In terms of membrane
changes, the mcr phenotype in Gram-negative bacteria is known to decrease the membrane charge
and increase its packing by the chemical modification of the outer membrane. In this sense, the cationic
additions reduce the negative charge and limit antimicrobial peptide binding and membrane disruption.
These modifications make the outer membrane more resistant to antimicrobial peptides, and suggest
that LPS modification prevents the penetration of large molecules through a strengthening of lateral
interactions between neighboring LPS molecules. When lipid packing increases, the area-per-lipid
in the outer membrane is reduced, and polymyxin penetration drastically decreases, as the drug
preferably lies flat on the membrane and does not penetrate the cell. In general, a greater packing of
lipids is believed to lower the damage caused by polymyxin, corresponding to resistance [127].
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Table 2. The 10 discovered variants of the mobilized colistin resistance (mcr) gene, with their species
and country of first detection, as well as their sequence homology to mcr-1.
mcr Gene Type
mcr-1
mcr-2
mcr-3
mcr-4
mcr-5
mcr-6
mcr-7
mcr-8
mcr-9
mcr-10

Species of
First Detection

Country of
First Detection

Sequence Homology
to mcr-1 (%)

Strain Information

Reference

Escherichia coli
E. coli
E. coli
Salmonella enterica
serovar Typhimurium
S. enterica subsp.
enterica
Moraxella
pluranimalium
Klebsiella pneumoniae
K. pneumoniae
S. enterica subsp.
enterica
Enterobacter
roggenkampii

China
Belgium
China

100
76.7
45

SHP45
CP011374
WJ1

[123]
[128]
[129]

Italy

34

R3445

[130]

Germany

63.89

11-00422

[131]

Great Britain

62

248-01T/DSM-22804)

[132]

China
China

65
31.08

SC20141012
KP91

[133]
[134]

New York

63

GCF_002091095.1

[135]

China

29.31

090065
(WCHER090065)

[125]

Molecular investigations of the genetic background of mcr genes have confirmed them on three
major types of plasmids: IncI2, IncHI2 and IncX4, in addition to IncHI1, IncF, IncFI, IncFIB, IncFII, IncP,
IncP-1, IncK2 and phage-like IncY [7]. Some but not all plasmids carrying the mcr-1 gene harbor other
antimicrobial resistance genes to other antibiotics including β-lactams, aminoglycosides, quinolones,
fosfomycin, sulfonamides, and tetracyclines. Hence, the location of this gene on multidrug resistance
plasmids is worrisome because using other antimicrobials can selectively promote the growth of
isolates carrying mcr-1 and their subsequent spread [12]. More importantly, the mcr-1 gene has been
identified in highly drug-resistant pathogens harboring plasmids encoding carbapenemase genes,
such as blaNDM-1 , blaNDM-5 , blaOXA-48 , blaKPC-2 , and blaVIM-1 , significantly complicating the therapy of
infections caused by such bacteria [136,137].
The origin and associated sequences of the plasmid-encoded mcr remain the subject of intensive
investigation, and remarkable progress in knowledge pertaining to these details is notable. In addition
to the plasmid types and up to 10 variants of the gene reported so far, the insertion sequence of
ISApl1 was identified to flank one or both ends of mcr-1, suggesting that this gene was mobilized by
an ISApl1 composite transposon which has, in some cases, subsequently lost one or both copies of
ISApl1 [138,139]. The transposon Tn6330 was found to be the key element mediating the translocation of
mcr-1 into various plasmid backbones through the formation of a circular intermediate, and it allows the
co-transmission of mcr-1 with other resistance determinants through IncHI2 plasmids [140]. The genetic
structure harboring the gene is known as “mcr-1 cassette”, that has a length of 2600 bp, and was found
to carry its own promoter sequences driving the expression of mcr-1 [12]. Recently, a comprehensive
analysis of all mcr-1 sequences in GenBank was used to identify a chromosomal region of a novel
Moraxella species, with significant homology to the mcr-1 structure, and which likely represents the
origin of this gene. All mcr-1 structures lacking one or both flanking ISApl1 were obtained from
ancestral composite transposons that subsequently lost the insertion sequences by a process of abortive
transposition. The mobilization of mcr-1 occurs as part of a composite transposon and structures
lacking the downstream ISApl1 are not capable of gene mobilization [141]. The combination of the
ISApl1 and the mcr-1 cassette has been described on the chromosome of an E. coli isolate recovered in
2015 from raw chicken meat in Switzerland, suggesting the possible hypothesis that mcr genes are
capable of integration and therefore stabilization in some bacterial chromosomes [142].
Epidemiologic data regarding mcr genes are also becoming more accessible. In a recent
meta-analysis involving over 200 studies from 47 different countries across six continents [65],
the overall prevalence of mcr genes ranged between 0.1% and 9.3%, with the highest number of
mcr-positive strains reported in China. Approximately 95% of mcr genes were of the type mcr-1.
The highest prevalence was in the environment (22%), followed by animals (11%), food (5.4%),
and humans (2.5%). Pathogenic E. coli (54%), isolated from animals (52%) and harboring an IncI2
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plasmid (34%) were the species with highest prevalence of mcr genes. The significant role of food
chain and/or the environment in mcr gene spreading is, therefore, evident and warrants further
investigation. Given such a global burden of mcr gene carriage, its reservoirs, and its dissemination
has triggered extensive worldwide alarms [143]. Large-scale investigations are urgently required for
a better understanding of the molecular epidemiology and resistance mechanisms of these genes.
The proper understanding of transferable polymyxin resistance shall provide evidence to improve
clinical therapeutics targeting severe infections by mcr-harboring pathogens [144].
6. Special Features and Spread of Polymyxin Resistance among Prominent
Gram-Negative Pathogens
The features of polymyxin resistance exhibit some specific distinctions among important
Gram-negative pathogens, namely those of the family Enterobacteriaceae, P. aeruginosa and A. baumannii.
These special features are differentiated below and summarized in Table 3.
6.1. Enterobacteriaceae
Among the family Enterobacteriaceae, polymyxin resistance has been described for many species,
including Escherichia, Klebsiella, Salmonella, Shigella, Enterobacter, and Citrobacter [145,146], (Table 3).
Several molecular mechanisms have been identified, primarily the modification of LPS through the
addition of the cationic groups L-Ara4N and pEtN [99]. Specifically, fine gene alterations are responsible
for the LPS modifications seen in members of the Enterobacteriaceae family, and they can be variable
among the different species.
Table 3. Examples of chromosomal and plasmid-encoded polymyxin resistance mechanisms described
in Enterobacteriaceae, Pseudomonas, and Acinetobacter.
Chromosomal Resistance

Klebsiella
pneumoniae

Enterobacteriaceae
E. coli

Two-component
systems [ref]

Additional mechanisms [ref]

PhoPQ [103]
PmrAB [147]

Shedding of capsular polysaccharide capable of
trapping polymyxins [148]
Overexpression of the efflux pump kpnEF [149]

PhoPQ [151]
PmrAB [112]

Modification of Kdo
(3-deoxy-D-manno-octulosonic acid) [152]

PhoPQ [155]
PmrAB [156]

Inhibition of expression of outer membrane
proteins OmpF and/or OmpC [157]

Pseudomonas

PhoPQ [159]
PmrAB [160]
CprRS [161]
ColRS [110]
ParRS [162]

Efflux pump MexXY/OprM [163]
Lipid A diacylation [164]
Chromosomal mcr-5 [165]

Acinetobacter

PmrAB [167]

Expression of the efflux pump EmrAB [168]

Salmonella

Plasmid-Encoded Resistance
mcr type

Ref

mcr-1

[108]

mcr-2

[108,150]

mcr-7

[133]

mcr-8

[134]

mcr-1

[123]

mcr-2

[153]

mcr-3

[129]

mcr-4

[154]

mcr-5

[154]

mcr-4

[130]

mcr-5

[158]

mcr-1

[166]

mcr-1

[166]

mcr-4.3

[169]

As far as K. pneumoniae is concerned, it is known that a profound molecular mechanism that leads
to the emergence of polymyxin resistance in this organism is the mutation/inactivation of the mgrB
gene, as described above in Section 5.1 [104]. The gene mgrB is a conserved gene of 141 nucleotides
in length, encoding a short, 47-amino acid protein that causes negative feedback on the PhoPQ
regulatory system. Another proposed mechanism that may occur on K. pneumoniae is the shedding of
capsular polysaccharides from its capsulated surface [148,170]. These capsular compounds have the
capability of binding to or trapping polymyxins, thereby depleting drug concentrations reaching the
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bacterial membranes, and increasing resistance. The proposed binding is a function of the electrostatic
interactions between the cationic polymyxins and anionic capsular polysaccharides [171]. Additionally,
in a report from India, it was found that a mutant form of the efflux pump KpnEF may increase
sensitivity to colistin in K. pneumoniae. This pump belongs to the small multidrug resistance (SMR)
protein family and is composed of four transmembrane alpha-helices that span the outer membrane
and the cytoplasmic membrane. This finding raises the probability that the efflux pump overexpression
may contribute to colistin resistance in this organism (Table 3) [149].
In E. coli, and parallel to the mgrB mechanism, mgrR is a key genetic determinant of
polymyxin resistance in this organism [63]. The mgrR mediates the modification of the outer
Kdo (3-deoxy-D-manno-octulosonic acid) residues of LPS by adding pEtN [152]. In Salmonella,
the gene mig-14 has been recently shown to contribute to polymyxin resistance through the decreasing
permeability of the organism’s outer membrane and endorsing biofilm formation. The reduction in
permeability is thought to occur through the ability of mig-14 to suppress or inhibit the expression of
outer membrane proteins OmpF and/or OmpC [157].
Apart from the above chromosomal gene alterations, Enterobacteriaceae were the first reservoir of
the transferrable polymyxin resistance, with the plasmid-encoded gene mcr-1 being first reported in
November 2015 from E. coli [123]. Horizontal spread accounted for the easy dissemination of mcr genes
among other members of the family. To date, E. coli remains the most prevalent species among the
mcr-positive isolates, accounting over 90% of the total mcr-carrying isolates, followed by Salmonella enterica
(7%) then K. pneumoniae (2%). As of 2019, mcr has been detected in Enterobacteriaceae in 47 different
countries [7]. Animals are believed to be the main reservoir of mcr, and this is attributed in part to the
heavy use of polymyxins in veterinary medicine for prophylactic purposes, and in part due to genetic
background. These genes are often associated with blaCMY-2 and florR genes, which are found in animal
enterobacterial isolates, and also with an insertion sequence, ISApl1, known in Pasteurella multocida,
an animal pathogen [172]. Nowadays, Enterobacteriaceae harboring mcr genes are recovered from patients
and healthy subjects [173], hospital surfaces [174], raw meat [123], livestock [175], fresh vegetables [176],
wild birds [177], and surface samples from public transportation [178], indicating community spread.
Moreover, mcr genes are being detected in enterobacterial isolates with other resistance genes. In Tunisia,
E. coli isolates with both CTX-M-15 and mcr-1 were recovered from bovine fecal samples and raw
goat milk [179]. In Brazil, the emergence of a K. pneumoniae isolate with both blaKPC and mcr-1 was
reported [180]; likewise, the same gene combination was found in Enterobacteriaceae growing in streams
and wastewater treatment plants in Italy [181]. It is noteworthy to mention that mcr-1 was detected in
Switzerland on the chromosome of an E. coli isolate recovered from chicken [142], suggesting that it may
be integrated and stabilized in an enterobacterial genome.
Worldwide, the rates of polymyxin resistance in Enterobacteriaceae are widely variable. In K. pneumoniae,
it reaches about 9% worldwide, while in some European countries such as Italy, Greece, Spain, and Hungary,
it may rise up to 43%, 20.8% in Greece and over 30% in Spain [4]. In Dubai, the resistance of Enterobacteriaceae
isolates to colistin was 27% [182]. Considering the further limitations of the antimicrobial options available
for the management of infections caused by MDR Enterobacteriaceae, there is no doubt that the recent
reports of polymyxin resistance in these pathogens raises major concerns, and stresses the need for better
surveillance and infection control.
6.2. Pseudomonas aeruginosa
P. aeruginosa is a Gram-negative opportunistic pathogen of hospitalized and immunocompromised
patients, causing severe infections and representing a challenge to infection control. Polymyxins
represent the last antibiotic option for P. aeruginosa infections [183]. Five two-component systems that
regulate LPS modifications are known to mediate polymyxin resistance in P. aeruginosa (Table 3) [12].
Much alike has been seen in Enterobacteriaceae, where alterations in the PmrAB [160,184,185]
and PhoPQ [159] systems have been shown to intervene in acquired resistance to colistin. One report
indicated that there is a differential role for these systems, where resistance was caused by both the
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inactivation and/or amino acid substitutions in PhoQ, while resistance was caused only by amino acid
substitutions of PmrB. Meanwhile, the alteration of both PhoQ and PmrB resulted in higher levels of
resistance than the alteration of either component alone [186].
The remaining three types of two-component systems shown to participate in colistin resistance
in P. aeruginosa, are the CprRS [161], and ColRS [110] ParRS [162] systems. Mutations in the ColRS
and CprRS two-component regulatory systems may play a major role, since the association of mutations
in the PhoQ gene and mutations in the colS or cprS genes confers a high level of polymyxin resistance [110].
The action of the ColRS and CprRS systems may occur through the activation of PhoQ gene and/or
through other genes that are yet to be identified [12]. Furthermore, the ParRS (polymyxin adaptive
resistance) two-component system is involved in adaptative resistance to polymyxins. Mutations
in this system cause the constitutive expression of pmrHFIJKLM operon with a resulting addition of
L-Ara4N to the LPS [187].
In addition to the above mechanisms, and very recently, Puja and colleagues showed that the
efflux pump MexXY/OprM was important in the adaptation of P. aeruginosa to polymyxins, unlocking
a new perspective for restoring its susceptibility by the suggested use of efflux inhibitors [163]. In an
experimental simulation of infections, where P. aeruginosa cells were cultured in the presence of cell
wash fluids containing LPS, cell-free LPS derived from bacterial cells inhibited the antimicrobial
activity of colistin. This indicated that large amounts of broken and dead cells of P. aeruginosa at
infection sites may reduce colistin effectiveness, even in cells that have not yet acquired resistance [188].
Moreover, an investigation using lipidomics and transcriptomics discovered that polymyxin B induces
lipid A deacylation in P. aeruginosa. This mechanism is considered an “innate immunity” response to
polymyxins and a compensatory mechanism to L-Ara4N modification, and thus high-level polymyxin
resistance in P. aeruginosa. The less hydrophobic lipid A with five acyl residues decreased polymyxin B
penetration, compared to the normal form with six residues instead [164].
Transferable polymyxin resistance, represented by the spread of mcr genes, has been recently
rising in P. aeruginosa, following its initial observation in Enterobacteriaceae. Perhaps the first report
of mcr in P. aeruginosa originated from Maryland, USA, in 2018, when Snesrud and Colleagues,
through whole-genome sequencing, discovered a chromosomally encoded mcr-5 gene carried within a
transposon in a colistin-nonsusceptible P. aeruginosa [165]. Following that report, another single isolate
of P. aeruginosa harboring mcr-1 was detected during a multihospital survey on polymyxin resistance
in Pakistan in 2019 [166]. The origin, transmissibility, and prevalence of mcr genes in P. aeruginosa
remains to be further identified.
The spread of P. aeruginosa resistant to polymyxins is variable worldwide. In a survey from
Taiwan, the rate of resistance was close to 9% [189], which was about 6% in a German university
hospital [190], 5% in Spain [191], 4% in Korea [192], and 2% in Thailand [193]. In a cross-sectional,
multicenter survey from Dubai, all the studied P. aeruginosa isolates were colistin sensitive [194]. On
the other hand, the rate of resistance was 22% in a report from India [195], and 15% in a nationwide
Italian survey [196]. Ongoing surveillance is needed on a global scale, to observe and mitigate the
spread of polymyxin resistance in this hostile pathogen.
6.3. Acinetobacter baumannii
Nosocomial infections with A. baumannii constitute a global problem, with high mortality rates
and resistance to most antibiotics [197]. The rapid emergence of resistance in this top priority pathogen
has revived clinical interest in polymyxins. However, resistance to this class of antibiotics in A. baumannii
is on the rise [116]. Although the current rate of polymyxin-resistant A. baumannii represents less than
1% of clinical isolates, these still pose a significant challenge to public health authorities [198].
The main mechanism of polymyxins resistance in A. baumannii is chromosomally encoded,
and relies on spontaneous mutations in lipid A biosynthesis genes, lpxA, lpxC, or lpxD, where LPS is
not formed, and interaction with polymyxins is lost [199]. Mutations detected in those genes were
either substitutions, truncations, frameshifts, or insertional inactivation by the insertion sequence
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ISAba11 [200]. Moreover, the addition of cationic groups to the LPS can occur in A. baumannii and is
mediated by mutations in PmrAB [201]. On another note, the overexpression of genes corresponding
to reduced fluidity and the increased osmotic resistance of the outer membrane, known as lpsB, lptD,
and vacJ, was shown to contribute to polymyxins’ resistance in A. baumannii [202]. In a strain of
A. baumannii with laboratory-induced polymyxin resistance, the expression of the efflux pump EmrAB
was found to be high, validating the possible association between EmrAB efflux pumps and the
decreased sensitivity to polymyxins in A. baumannii. Nevertheless, the clinical implications of this
association remain to be tested [168]. In 2018, a study from Australia showed that an extra copy of the
insertion sequence element ISAba125 within a gene encoding an H-NS family transcriptional regulator
of A. baumannii, contributed to pEtN transferase and colistin resistance [203].
The conventional, chromosomally encoded resistance to polymyxins in A. baumannii has a limited
spread. However, the plasmid-borne mcr gene has been recently described in A. baumannii. There have
recently been reports of mcr-4 from the Czech Republic [204], mcr-1 from Pakistan [166], as well
as mcr-4.3 from China [169] and Brazil [205]. The explication of genotypic profiles and resistance
mechanisms are essential to control resistance to polymyxins in A. baumannii, thereby preserving this
antibiotic class as a treatment option.
7. Future Implications
With the necessity of polymyxins for the management of MDR infections, it is anticipated,
like what has been seen with other classes of antibiotics, novel generation polymyxins will be sought.
Therefore, improving the properties of the two clinically available polymyxins shall be of prodigious
interest to researchers focusing on antimicrobial development. Over the last decade, and in light of
the augmented research on polymyxin pharmacology, the mode of action and toxicity, as well as the
chemical and molecular elucidation of resistance, investigations have yielded a number of promising
pathways to boost polymyxins efficacy and safety and reduce bacterial resistance [8].
For example, and in terms of medicinal chemistry, it was discovered that the incorporation
of amino acid residues with long lipophilic alkyl or biphenyl side chains, such as octyl-glycine
and biphenylalanine, at positions 6 or 7 of the polymyxin molecule, resulting in better activity against
resistant isolates [206]. The observation that the N-terminal fatty acyl chain represents a major cause
for nephrotoxicity, has directed chemical modification efforts to re-construct polymyxins by focusing
not only on the N-terminal fatty acyl group, but also to look beyond the peripheries of the polymyxin
scaffold and examine all the amino acid residues within the polymyxin core structure. This has
given rise to exciting novel compounds, which should be further refined to structurally uncouple the
antimicrobial activity from nephrotoxicity [25].
Other efforts are focusing on modified polymyxin formulations or synergistic combinations that
decrease toxicity; Yu and colleagues have recently developed an inhalable liposomal mixture of colistin
and ciprofloxacin, that showed high effectiveness against P. aeruginosa [207]. Other interesting formulations of
polymyxins are structured gels based on natural and synthetic polymers [208]. For example, phenylboronic
acid polycarbonate hydrogels, that are loaded with polymyxin B, demonstrated in vitro antimicrobial
efficacy against P. aeruginosa from burn wound infections [209]. The use of microneedles for the transdermal
delivery of drugs into the systemic circulation was also investigated for polymyxins. A microneedle
system composed of sugar, polyvinylpyrrolidone and encapsulated polymyxin B, was developed and used
against Salmonella typhimurium, with the achievement of a high antibiotic level in models of porcine
skin [210,211]. Innovative delivery systems of polymyxins include microparticles, nanoparticles, liposomes,
and niosomes [208]. A niosome is a non-ionic vesicle comprising a non-ionic surfactant and cholesterol,
and can incorporate both hydrophilic drugs (in its aqueous layer) and lipophilic drugs (in its vesicular
lipid membrane) [212]. Niosomes can enhance the delivery of poorly absorbable drugs and increase
drug absorption and bioavailability by the penetration of the GIT barrier. Polymyxin B niosomes were
formulated using sorbitan monostearate surfactant and cholesterol to improve intestinal permeability.
They protected polymyxin B from the GIT environment and increased its absorption within the normal
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limits of nephrotoxicity, indicating that niosomes improve the oral bioavailability of polymyxin B. There is
no increase in the side effects with this mode of delivery [213]. Therefore, the improved delivery and actions
of polymyxins shall be obtained by a blend of chemistry, nanotechnology, and pharmaceutics.
The recent trending strategy in testing FDA-approved medications that have no antibacterial
activity in combination with antibacterials to enhance the latter’s effect is being applied to polymyxins.
In a truly ground-breaking approach, researchers from Australia found that a combination of polymyxin
B and the selective serotonin reuptake inhibitor, sertraline, resulted in greater damage to P. aeruginosa,
highlighting the likely possibilities of this combination for the treatment of central nervous system
infections [214]. Moreover, the experimental antitumor compound PFK-158 was found to enhance
the activity of colistin and delay resistance emergence in mice infected with Enterobacteriaceae [215].
In clinical trials, colistin showed synergistic activity with the antiviral drug azidothymidine in the
management of urinary tract infections caused by mcr-1-producing E. coli [216]. A trial combining
polymyxin B with the estrogen modulator tamoxifen detected a remarkable decrease in the essential
precursor metabolites of L-Ara4N, interfering with a major mechanism of polymyxin resistance.
The combination had a synergistic bactericidal effect on polymyxin-resistant P. aeruginosa in a cystic
fibrosis metabolomic model [217].
Apart from such an approach, and considering the research on antimicrobial peptides other than
polymyxins, in a study testing experimental cationic antimicrobial peptides, Geitani and colleagues [218]
showed that the minimum inhibitory concentrations of colistin on P. aeruginosa were reduced by
eight-fold in the presence of these peptides, probably suggesting an interesting alternative combination
for resistant strains. Moreover, in a Turkish investigation on P. aeruginosa biofilms that were initially
resistant to therapeutic concentrations of antibiotics, colistin was synergistic with antimicrobial
peptides for inhibiting the attachment of bacterial cells to a biofilm surface as well as inhibiting biofilm
formation [219]. Such examples may prove useful in future attempts to combine polymyxins with
antimicrobial peptides as an interesting alternative mode of treatment of MDR pathogens.
In brief, industry and research groups across the globe are still gearing up to develop new
polymyxins that are safer and more effective than the currently approved polymyxin B and colistin.
For instance, avoiding direct modifications to the polymyxin scaffold while attempting to mimic the
physicochemical properties of polymyxins resulted in a series of cyclic amphipathic peptides consisting
of alternating cationic and nonpolar amino acid residues, loosely based on the amphipathic properties of
polymyxins. These compounds displayed potent antimicrobial activity and a high affinity for LPS [220].
A study by a group from the U.K. and U.S.A. recently reported a series of promising next generation
polymyxin nonapeptides with an amine-containing N-terminal moiety of specific regional conformation
and stereochemistry. These compounds demonstrated superior in vitro activity and inferior cytotoxicity
compared to polymyxin B. A subgroup of these compounds having a β-branched aminobutyrate
N-terminus with an aryl substituent also offered low cytotoxicity, and candidates were selected for
additional development [221]. The future holds potential for these drug discovery and development
programs to bring upgraded polymyxins or novel polymyxin-including combinations from the bench
into the clinic.
8. Conclusions
To date, significant progress has been made in understanding the activity of polymyxins
and unraveling bacterial resistance mechanisms to this refreshed category of antibacterial compounds.
However, additional investigations are still underway to obtain a better understanding of membrane
interactions, bacterial resistance, and improved clinical utility. In light of increasing resistance to
polymyxins, there is a critical need for restricting their use, as well as for effective infection prevention
and control measures. Integrated efforts should aim at the robust enquiry of the molecular epidemiology
of resistance, and the surveillance of rates and dissemination of resistance among humans, animals,
and the environment. The spread of the plasmid-mediated mcr-1 resistance gene is a principal culprit
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to polymyxins, which, if unlimited, the real devastating loss of a life-saver antibiotic class may
happen soon.
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